Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oxidative Stress | 26 | 2024 | 58 | 7.790 |
Why?
|
| Anxiety | 20 | 2021 | 167 | 4.510 |
Why?
|
| Stress, Psychological | 11 | 2022 | 86 | 4.200 |
Why?
|
| Refugees | 5 | 2024 | 13 | 3.940 |
Why?
|
| Stress Disorders, Post-Traumatic | 9 | 2024 | 62 | 3.390 |
Why?
|
| Animals | 41 | 2024 | 1711 | 2.780 |
Why?
|
| Maze Learning | 13 | 2024 | 22 | 2.460 |
Why?
|
| Hypertension | 6 | 2020 | 58 | 2.340 |
Why?
|
| Rats | 24 | 2024 | 241 | 2.260 |
Why?
|
| Vitis | 5 | 2017 | 7 | 2.220 |
Why?
|
| Memory Disorders | 12 | 2024 | 36 | 2.200 |
Why?
|
| Male | 33 | 2024 | 2491 | 2.200 |
Why?
|
| Brain | 11 | 2021 | 195 | 2.180 |
Why?
|
| Hippocampus | 8 | 2024 | 59 | 2.160 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2021 | 125 | 2.100 |
Why?
|
| Neuroprotective Agents | 4 | 2024 | 13 | 2.050 |
Why?
|
| Sleep Deprivation | 4 | 2019 | 9 | 1.990 |
Why?
|
| Antioxidants | 8 | 2024 | 23 | 1.870 |
Why?
|
| Vehicle Emissions | 3 | 2021 | 5 | 1.860 |
Why?
|
| Behavior, Animal | 10 | 2021 | 20 | 1.840 |
Why?
|
| Inflammation | 7 | 2019 | 57 | 1.740 |
Why?
|
| Memory | 4 | 2024 | 39 | 1.630 |
Why?
|
| Disease Models, Animal | 15 | 2017 | 225 | 1.560 |
Why?
|
| Cyclic N-Oxides | 4 | 2016 | 7 | 1.490 |
Why?
|
| Rats, Wistar | 8 | 2024 | 31 | 1.450 |
Why?
|
| Plant Extracts | 3 | 2017 | 15 | 1.370 |
Why?
|
| Corticosterone | 12 | 2021 | 19 | 1.370 |
Why?
|
| Mental Disorders | 4 | 2024 | 48 | 1.370 |
Why?
|
| Aging | 4 | 2017 | 109 | 1.350 |
Why?
|
| Air Pollutants | 2 | 2021 | 8 | 1.220 |
Why?
|
| Motor Activity | 5 | 2017 | 61 | 1.120 |
Why?
|
| Mitochondria | 2 | 2020 | 20 | 1.110 |
Why?
|
| Neurons | 5 | 2021 | 109 | 1.050 |
Why?
|
| Physical Conditioning, Animal | 5 | 2017 | 29 | 1.040 |
Why?
|
| Humans | 17 | 2024 | 4936 | 1.000 |
Why?
|
| Female | 11 | 2024 | 2523 | 0.940 |
Why?
|
| Dominance-Subordination | 5 | 2017 | 5 | 0.920 |
Why?
|
| Aggression | 2 | 2015 | 14 | 0.910 |
Why?
|
| Pentoxifylline | 1 | 2024 | 1 | 0.880 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2024 | 9 | 0.880 |
Why?
|
| Social Class | 1 | 2024 | 20 | 0.860 |
Why?
|
| beta-Adrenergic Receptor Kinases | 4 | 2007 | 6 | 0.840 |
Why?
|
| Sex Characteristics | 2 | 2021 | 26 | 0.810 |
Why?
|
| Syria | 4 | 2024 | 5 | 0.800 |
Why?
|
| Anxiety Disorders | 2 | 2014 | 69 | 0.780 |
Why?
|
| Students | 2 | 2021 | 120 | 0.770 |
Why?
|
| Brain-Derived Neurotrophic Factor | 6 | 2014 | 19 | 0.770 |
Why?
|
| Buthionine Sulfoximine | 4 | 2016 | 4 | 0.750 |
Why?
|
| Superoxide Dismutase | 6 | 2024 | 11 | 0.740 |
Why?
|
| Rats, Long-Evans | 6 | 2020 | 19 | 0.730 |
Why?
|
| Propranolol | 2 | 2020 | 2 | 0.700 |
Why?
|
| Memory, Short-Term | 5 | 2015 | 43 | 0.700 |
Why?
|
| Academic Success | 1 | 2021 | 8 | 0.700 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2020 | 10 | 0.700 |
Why?
|
| Mental Health | 2 | 2024 | 57 | 0.700 |
Why?
|
| Lactoylglutathione Lyase | 7 | 2017 | 7 | 0.700 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 96 | 0.690 |
Why?
|
| Mitochondrial Dynamics | 1 | 2020 | 3 | 0.650 |
Why?
|
| Pandemics | 1 | 2021 | 73 | 0.640 |
Why?
|
| Reactive Oxygen Species | 1 | 2020 | 30 | 0.640 |
Why?
|
| Nadolol | 1 | 2020 | 10 | 0.640 |
Why?
|
| Depression | 6 | 2017 | 125 | 0.620 |
Why?
|
| Jordan | 3 | 2024 | 5 | 0.610 |
Why?
|
| Neural Pathways | 1 | 2019 | 31 | 0.600 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 9 | 0.590 |
Why?
|
| Antipsychotic Agents | 1 | 2019 | 48 | 0.570 |
Why?
|
| Dinoprost | 5 | 2021 | 5 | 0.550 |
Why?
|
| Maternal Behavior | 1 | 2017 | 11 | 0.540 |
Why?
|
| Health Impact Assessment | 1 | 2017 | 1 | 0.540 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 269 | 0.530 |
Why?
|
| Social Perception | 1 | 2017 | 15 | 0.530 |
Why?
|
| Air Pollution | 1 | 2017 | 11 | 0.530 |
Why?
|
| Mood Disorders | 1 | 2017 | 4 | 0.530 |
Why?
|
| Visual Perception | 2 | 2017 | 57 | 0.530 |
Why?
|
| Cognition Disorders | 1 | 2017 | 21 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2007 | 6 | 0.520 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2007 | 5 | 0.520 |
Why?
|
| Fruit | 2 | 2015 | 12 | 0.510 |
Why?
|
| Resilience, Psychological | 1 | 2017 | 16 | 0.500 |
Why?
|
| Central Nervous System | 1 | 2016 | 7 | 0.500 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 258 | 0.500 |
Why?
|
| Gene Expression Regulation | 3 | 2013 | 73 | 0.490 |
Why?
|
| Catecholamines | 2 | 2021 | 8 | 0.480 |
Why?
|
| Glutathione Reductase | 5 | 2013 | 5 | 0.460 |
Why?
|
| RGS Proteins | 2 | 2015 | 2 | 0.460 |
Why?
|
| Phytotherapy | 1 | 2015 | 5 | 0.460 |
Why?
|
| Plant Preparations | 1 | 2014 | 1 | 0.450 |
Why?
|
| Spin Labels | 4 | 2016 | 7 | 0.430 |
Why?
|
| Social Behavior | 1 | 2014 | 22 | 0.420 |
Why?
|
| Glutathione | 3 | 2024 | 7 | 0.420 |
Why?
|
| Depressive Disorder | 1 | 2014 | 12 | 0.420 |
Why?
|
| Estrogens | 1 | 2013 | 21 | 0.400 |
Why?
|
| Sodium Chloride, Dietary | 1 | 2013 | 6 | 0.400 |
Why?
|
| Random Allocation | 4 | 2020 | 17 | 0.400 |
Why?
|
| Diet | 1 | 2013 | 40 | 0.390 |
Why?
|
| Cognition | 1 | 2014 | 140 | 0.390 |
Why?
|
| Time Factors | 4 | 2015 | 163 | 0.370 |
Why?
|
| Spatial Memory | 2 | 2024 | 8 | 0.350 |
Why?
|
| Homeostasis | 1 | 2011 | 29 | 0.340 |
Why?
|
| Texas | 2 | 2022 | 190 | 0.340 |
Why?
|
| Exercise Test | 2 | 2013 | 41 | 0.330 |
Why?
|
| Insulin Resistance | 1 | 2010 | 6 | 0.330 |
Why?
|
| Powders | 3 | 2015 | 3 | 0.330 |
Why?
|
| Mice | 5 | 2024 | 685 | 0.330 |
Why?
|
| Blotting, Western | 5 | 2011 | 17 | 0.320 |
Why?
|
| Adolescent | 2 | 2024 | 758 | 0.300 |
Why?
|
| Young Adult | 2 | 2024 | 787 | 0.300 |
Why?
|
| Oxygen Consumption | 2 | 2020 | 23 | 0.280 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2007 | 1 | 0.270 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2007 | 6 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2006 | 1 | 0.260 |
Why?
|
| Adult | 2 | 2024 | 1567 | 0.260 |
Why?
|
| Alzheimer Disease | 3 | 2013 | 62 | 0.260 |
Why?
|
| Housing, Animal | 2 | 2017 | 5 | 0.240 |
Why?
|
| Glutathione Peroxidase | 1 | 2024 | 1 | 0.220 |
Why?
|
| Stress, Physiological | 2 | 2015 | 26 | 0.220 |
Why?
|
| Lipid Peroxidation | 1 | 2024 | 2 | 0.220 |
Why?
|
| Vitamin E | 1 | 2024 | 1 | 0.220 |
Why?
|
| Streptozocin | 1 | 2024 | 6 | 0.220 |
Why?
|
| Aerosols | 1 | 2024 | 3 | 0.220 |
Why?
|
| Signal Transduction | 4 | 2011 | 216 | 0.220 |
Why?
|
| Blood Glucose | 1 | 2024 | 29 | 0.220 |
Why?
|
| Histones | 2 | 2014 | 12 | 0.220 |
Why?
|
| Educational Status | 1 | 2024 | 29 | 0.220 |
Why?
|
| Exploratory Behavior | 2 | 2017 | 8 | 0.210 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2024 | 18 | 0.210 |
Why?
|
| Lupus Vasculitis, Central Nervous System | 1 | 2024 | 2 | 0.210 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 27 | 0.210 |
Why?
|
| G-Protein-Coupled Receptor Kinase 3 | 4 | 2007 | 4 | 0.210 |
Why?
|
| Long-Term Potentiation | 3 | 2013 | 5 | 0.200 |
Why?
|
| Cell Survival | 2 | 2016 | 54 | 0.200 |
Why?
|
| Cell Line | 2 | 2016 | 84 | 0.200 |
Why?
|
| Darkness | 2 | 2015 | 4 | 0.200 |
Why?
|
| Blood Pressure | 2 | 2013 | 40 | 0.200 |
Why?
|
| Early Detection of Cancer | 1 | 2023 | 7 | 0.200 |
Why?
|
| Health Status | 1 | 2023 | 27 | 0.190 |
Why?
|
| Epinephrine | 3 | 2014 | 8 | 0.190 |
Why?
|
| Analysis of Variance | 3 | 2013 | 70 | 0.190 |
Why?
|
| Brain Chemistry | 2 | 2013 | 5 | 0.190 |
Why?
|
| Gene Expression | 2 | 2013 | 49 | 0.180 |
Why?
|
| Perception | 1 | 2022 | 32 | 0.180 |
Why?
|
| Teaching | 1 | 2021 | 11 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2022 | 98 | 0.180 |
Why?
|
| Faculty | 1 | 2021 | 15 | 0.180 |
Why?
|
| Brain Stem | 1 | 2021 | 1 | 0.180 |
Why?
|
| Bromine | 1 | 2021 | 1 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2022 | 47 | 0.170 |
Why?
|
| Estradiol | 1 | 2021 | 16 | 0.170 |
Why?
|
| Xanthine | 2 | 2011 | 2 | 0.170 |
Why?
|
| Xanthine Oxidase | 2 | 2011 | 3 | 0.170 |
Why?
|
| Up-Regulation | 4 | 2013 | 28 | 0.170 |
Why?
|
| Educational Measurement | 1 | 2021 | 49 | 0.170 |
Why?
|
| Universities | 1 | 2021 | 80 | 0.160 |
Why?
|
| Inhalation Exposure | 1 | 2020 | 1 | 0.160 |
Why?
|
| Nitric Oxide Synthase | 1 | 2020 | 2 | 0.160 |
Why?
|
| Superoxides | 1 | 2020 | 5 | 0.160 |
Why?
|
| Middle Aged | 1 | 2024 | 967 | 0.160 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2024 | 4 | 0.160 |
Why?
|
| Retrospective Studies | 1 | 2021 | 341 | 0.150 |
Why?
|
| Kidney | 1 | 2020 | 51 | 0.150 |
Why?
|
| Calpain | 2 | 2011 | 2 | 0.150 |
Why?
|
| Biomarkers | 2 | 2021 | 81 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 16 | 0.150 |
Why?
|
| Locomotion | 1 | 2019 | 11 | 0.150 |
Why?
|
| Animals, Newborn | 1 | 2019 | 31 | 0.150 |
Why?
|
| CA1 Region, Hippocampal | 3 | 2013 | 8 | 0.150 |
Why?
|
| Interpersonal Relations | 1 | 2019 | 53 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 33 | 0.140 |
Why?
|
| United States | 1 | 2021 | 495 | 0.140 |
Why?
|
| Postpartum Period | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cell Line, Tumor | 3 | 2007 | 160 | 0.140 |
Why?
|
| Drinking | 1 | 2017 | 4 | 0.130 |
Why?
|
| Psychological Tests | 1 | 2017 | 9 | 0.130 |
Why?
|
| Cell Line, Transformed | 1 | 2017 | 6 | 0.130 |
Why?
|
| Equipment Design | 1 | 2017 | 68 | 0.130 |
Why?
|
| Body Weight | 1 | 2017 | 58 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2016 | 7 | 0.130 |
Why?
|
| RNA, Messenger | 2 | 2007 | 68 | 0.120 |
Why?
|
| Immune System | 1 | 2016 | 11 | 0.120 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2016 | 7 | 0.120 |
Why?
|
| Cell Shape | 1 | 2016 | 9 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2016 | 19 | 0.120 |
Why?
|
| Isoprostanes | 1 | 2015 | 1 | 0.120 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 35 | 0.120 |
Why?
|
| Memory, Long-Term | 1 | 2015 | 4 | 0.120 |
Why?
|
| Learning | 2 | 2013 | 44 | 0.110 |
Why?
|
| Infusion Pumps | 1 | 2015 | 1 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2015 | 2 | 0.110 |
Why?
|
| Models, Animal | 1 | 2015 | 24 | 0.110 |
Why?
|
| Amygdala | 1 | 2015 | 5 | 0.110 |
Why?
|
| Emotions | 1 | 2016 | 75 | 0.110 |
Why?
|
| Rats, Inbred F344 | 1 | 2015 | 21 | 0.110 |
Why?
|
| Histone Deacetylases | 1 | 2014 | 2 | 0.110 |
Why?
|
| Norepinephrine | 1 | 2014 | 4 | 0.110 |
Why?
|
| Dopamine | 1 | 2014 | 26 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2015 | 34 | 0.110 |
Why?
|
| Neuroimmunomodulation | 1 | 2014 | 1 | 0.110 |
Why?
|
| Acetylation | 1 | 2014 | 6 | 0.110 |
Why?
|
| Anhedonia | 1 | 2014 | 4 | 0.110 |
Why?
|
| Social Dominance | 1 | 2013 | 1 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2013 | 4 | 0.100 |
Why?
|
| Deoxyguanosine | 1 | 2013 | 1 | 0.100 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 1 | 0.100 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2013 | 1 | 0.100 |
Why?
|
| Food, Preserved | 1 | 2013 | 1 | 0.100 |
Why?
|
| Freeze Drying | 1 | 2013 | 2 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2014 | 177 | 0.100 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2013 | 7 | 0.100 |
Why?
|
| Amyloid beta-Peptides | 2 | 2013 | 15 | 0.100 |
Why?
|
| Dietary Supplements | 1 | 2013 | 6 | 0.100 |
Why?
|
| Polyphenols | 1 | 2013 | 8 | 0.100 |
Why?
|
| Neuropsychological Tests | 1 | 2014 | 137 | 0.100 |
Why?
|
| Cytokines | 1 | 2012 | 37 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2011 | 9 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 21 | 0.090 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 15 | 0.090 |
Why?
|
| Protein Carbonylation | 1 | 2011 | 1 | 0.090 |
Why?
|
| DNA, Antisense | 1 | 2011 | 2 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 14 | 0.090 |
Why?
|
| Oxidants | 1 | 2011 | 3 | 0.090 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 3 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2012 | 66 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2011 | 13 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2011 | 5 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2011 | 15 | 0.090 |
Why?
|
| Light | 1 | 2011 | 43 | 0.080 |
Why?
|
| Radioimmunoassay | 1 | 2010 | 1 | 0.080 |
Why?
|
| Malondialdehyde | 1 | 2010 | 2 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 5 | 0.080 |
Why?
|
| Adaptation, Ocular | 1 | 2010 | 9 | 0.080 |
Why?
|
| Ganglionic Stimulants | 1 | 2009 | 5 | 0.080 |
Why?
|
| Nicotine | 1 | 2009 | 38 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2007 | 2 | 0.070 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2007 | 5 | 0.070 |
Why?
|
| Transcription Factor AP-2 | 1 | 2007 | 3 | 0.070 |
Why?
|
| Locus Coeruleus | 1 | 2007 | 4 | 0.070 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 1 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2007 | 1 | 0.060 |
Why?
|
| Phentolamine | 1 | 2007 | 1 | 0.060 |
Why?
|
| Benzophenanthridines | 1 | 2007 | 1 | 0.060 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2007 | 1 | 0.060 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2007 | 2 | 0.060 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2007 | 3 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2007 | 9 | 0.060 |
Why?
|
| Alkaloids | 1 | 2007 | 9 | 0.060 |
Why?
|
| Ionomycin | 1 | 2006 | 1 | 0.060 |
Why?
|
| Benzoquinones | 1 | 2006 | 1 | 0.060 |
Why?
|
| Lactams, Macrocyclic | 1 | 2006 | 1 | 0.060 |
Why?
|
| Immunoprecipitation | 1 | 2006 | 4 | 0.060 |
Why?
|
| Enzyme Stability | 1 | 2006 | 4 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2007 | 127 | 0.060 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 2006 | 1 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2006 | 16 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2024 | 33 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2024 | 5 | 0.050 |
Why?
|
| Proteinuria | 1 | 2024 | 10 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2024 | 47 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 2 | 2013 | 5 | 0.050 |
Why?
|
| Phenotype | 1 | 2024 | 67 | 0.050 |
Why?
|
| Calcineurin | 2 | 2013 | 11 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 184 | 0.050 |
Why?
|
| Synaptic Transmission | 2 | 2013 | 13 | 0.040 |
Why?
|
| Tryptophan Hydroxylase | 1 | 2021 | 1 | 0.040 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2021 | 1 | 0.040 |
Why?
|
| Neurotransmitter Agents | 1 | 2021 | 2 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2021 | 5 | 0.040 |
Why?
|
| Metabolome | 1 | 2021 | 4 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2021 | 10 | 0.040 |
Why?
|
| Brain Injuries | 1 | 2021 | 25 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2013 | 21 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 12 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2013 | 26 | 0.020 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2009 | 1 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 1 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2009 | 2 | 0.020 |
Why?
|
| Radioligand Assay | 1 | 2006 | 2 | 0.020 |
Why?
|
| Adrenergic Agonists | 1 | 2006 | 2 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 15 | 0.020 |
Why?
|
| Protein Transport | 1 | 2006 | 30 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 48 | 0.010 |
Why?
|
| Protein Binding | 1 | 2006 | 115 | 0.010 |
Why?
|